Market Overview

Zogenix Announces New Chief Commercial Officer

Zogenix (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced the appointment of R. Scott Shively to serve as executive vice president and chief commercial officer. Scott previously served as vice president - global commercial disease area lead for pain for Pfizer, Inc. Scott will be responsible for all of Zogenix's commercial strategies and operations including the currently marketed product, SUMAVEL® DosePro®, and the anticipated launch of the company's product candidate, ZohydroTM ER (hydrocodone bitartrate extended release capsules) which is pending FDA approval. In addition he will be a key member of the executive leadership team focused on strategic direction, product in-licensing, co-development opportunities and the established co-promotion with Covidien.

Scott has over 30 years of pharmaceutical industry experience in a variety of sales and marketing leadership positions including responsibility for early stage programs and an impressive list of successfully commercialized products, with extensive experience in pain. In his most recent role at Pfizer, Scott had global commercial leadership responsibility for Pfizer's primary care pain franchise including products such as Lyrica, Celebrex and Embeda, as well as for all pain

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Related Articles (ZGNX)

Around the Web, We're Loving...

Get Benzinga's Newsletters